Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiarrhythmic agent |
| gptkbp:administeredBy |
gptkb:tablet
extended-release tablet |
| gptkbp:approvedBy |
1980s
|
| gptkbp:ATCCode |
C01BC03
|
| gptkbp:brand |
Rythmol
Rytmonorm |
| gptkbp:CASNumber |
54063-53-5
|
| gptkbp:contraindication |
cardiogenic shock
electrolyte imbalance severe heart failure severe hypotension marked bradycardia |
| gptkbp:discoveredBy |
gptkb:Knoll_AG
|
| gptkbp:drugClass |
Class 1c antiarrhythmic
|
| gptkbp:eliminationHalfLife |
2-10 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C21H27NO3
|
| https://www.w3.org/2000/01/rdf-schema#label |
propafenone
|
| gptkbp:KEGGID |
D08411
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
sodium channel blocker
beta-adrenergic blocking activity |
| gptkbp:MeSH_ID |
D011345
|
| gptkbp:metabolism |
gptkb:CYP1A2
gptkb:CYP2D6 gptkb:CYP3A4 liver |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
90-95%
|
| gptkbp:PubChem_CID |
CHEMBL1377
4945 DB01182 |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
vomiting dizziness hypotension bradycardia metallic taste worsening of arrhythmia |
| gptkbp:synonym |
propafenona
propafenonum |
| gptkbp:UNII |
Z9PA0B1YXN
|
| gptkbp:usedFor |
gptkb:atrial_fibrillation
ventricular arrhythmias treatment of cardiac arrhythmias paroxysmal supraventricular tachycardia |
| gptkbp:bfsParent |
gptkb:Class_I_antiarrhythmic_drugs
|
| gptkbp:bfsLayer |
5
|